Skip to main content
  • Saved

Commented on 's Post

  • 2 weeks 1 day
    Key Points
    • Novel study examining the correlation between KRAS status with outcomes following ICI monotherapy compared with that of chemoimmunotherapy in patients with PD-L1 of 50% or greater.
    • KRAS variants in NSCLC were related smoking history, higher PD-L1 expression, and responsiveness to ICI monotherapy.
    • In this study, researchers demonstrated an overall survival (OS) benefit for first-line pembrolizumab over chemotherapy in those with PD-L1 expression of 1% or more.
    • Improvement occurred regardless KRAS status—especially in patients with KRAS variants (median OS , 28 vs 11 months; hazard ratio [HR], 0.42;, 95% CI, 0.22-0.81) versus those without KRAS variants (mOS, 15 vs 12 months; HR, 0.86; 95% CI, 0.63-1.18).